Plasmodium vivax polymorphism in a clinical drug trial
Plasmodium vivax polymorphism in a clinical drug trial
复制标题
DOI：
10.1128/cdli.8.5.891-894.2001
复制
发表时间：
2001-09-01
期刊：
影响因子：
--
通讯作者：
Sharma, VP
中科院分区：
文献类型：
--
作者：
Adak, T;Valecha, N;Sharma, VP
从双盲随机临床药物试验的数据进行了分析，以找到两种抗复发药物，布拉喹和伯氨喹，对不同的复发形式的间日疟原虫感染的比较反应。一项为期1年的随访研究强烈表明，间日疟原虫红细胞前期发育的持续时间是一个多态性特征，表现为两种菌株的催眠虫负责原发感染后的早期和晚期表现。上半年短期复发率明显高于长期复发率，下半年则相反。临床药物反应数据显示，以短期复发为特征的催眠虫对当前给药剂量的任何一种抗复发药物均不敏感，而以长时间孵育为特征的催眠虫则显著敏感。
Data from a double-blind randomized clinical drug trial were analyzed to find the comparative responses of two antirelapse drugs, bulaquine and primaquine, against different relapsing forms of Plasmodium vivax infection. A 1-year follow-up study strongly suggests that the duration of preerythrocytic development of P. vivax is a polymorphic characteristic, exhibited by two strains of hypnozoites responsible for early and late manifestations after primary infection. Short-term relapses were significantly higher in the first half year than long-term relapses, and the reverse was true in the second half year. Clinical drug response data showed that the hypnozoites characterized for short-term relapse were not susceptible to either of the antirelapse drugs in the currently administered dose, whereas hypnozoites characterized for long incubation were significantly susceptible.